179. ウィリアムズ症候群 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 5 / 薬物数 : 14 - (DrugBank : 7) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 32
薬物ごとの開発者(Primary Sponsor)、臨床試験情報(抜粋)です。
Buspirone
Massachusetts General Hospital
2021 Phase 4 NCT04807517 United States;
COZAAR 50 mg comprimidos recubierto con pelicula
Programa de Medicina Molecular y Genética, Hospital Vall d´Hebron
2009 - EUCTR2007-006059-37-ES Spain;
LONOTEN
Hospices Civils de Lyon
2008 - EUCTR2006-005745-11-FR France;
LOSARTAN POTASICO
Programa de Medicina Molecular y Genética, Hospital Vall d´Hebron
2009 - EUCTR2007-006059-37-ES Spain;
LOSARTAN POTASSIUM
Programa de Medicina Molecular y Genética, Hospital Vall d´Hebron
2009 - EUCTR2007-006059-37-ES Spain;
Methylphenidate, fluoxetin, risperidone
The Chaim Sheba Medical Center
2001 Phase 4 NCT00768820 Israel;
Vitamin D
National Center for Research Resources (NCRR)
1998 - NCT00013962 United States;
Massachusetts General Hospital
2021 Phase 4 NCT04807517 United States;
COZAAR 50 mg comprimidos recubierto con pelicula
Programa de Medicina Molecular y Genética, Hospital Vall d´Hebron
2009 - EUCTR2007-006059-37-ES Spain;
LONOTEN
Hospices Civils de Lyon
2008 - EUCTR2006-005745-11-FR France;
LOSARTAN POTASICO
Programa de Medicina Molecular y Genética, Hospital Vall d´Hebron
2009 - EUCTR2007-006059-37-ES Spain;
LOSARTAN POTASSIUM
Programa de Medicina Molecular y Genética, Hospital Vall d´Hebron
2009 - EUCTR2007-006059-37-ES Spain;
Methylphenidate, fluoxetin, risperidone
The Chaim Sheba Medical Center
2001 Phase 4 NCT00768820 Israel;
Vitamin D
National Center for Research Resources (NCRR)
1998 - NCT00013962 United States;